¶ One-Carbon Metabolism in Neurodegeneration
Path: mechanisms/one-carbon-metabolism-neurodegeneration
¶ Overview
One-carbon metabolism is a complex network of interconnected biochemical pathways that facilitate the transfer of one-carbon units for essential cellular processes including DNA synthesis, DNA methylation, amino acid metabolism, and antioxidant defense. This metabolic system operates through the folate cycle, methionine cycle, and transsulfuration pathway, all of which are intimately connected and critically important for neuronal health. Dysregulation of one-carbon metabolism has been increasingly recognized as a significant contributor to neurodegenerative disease pathogenesis, particularly through effects on epigenetic regulation, homocysteine toxicity, antioxidant capacity, and neurotransmitter synthesis [1]. [@onecarbon2019]
The brain is particularly vulnerable to one-carbon metabolism disturbances due to its high metabolic demand, limited regenerative capacity, and the blood-brain barrier's strict regulation of metabolite transport. Neurons rely heavily on proper function of these pathways for DNA repair, myelin maintenance, and neurotransmitter synthesis—all processes fundamental to neuronal survival and function. [@serine2015]
¶ One-Carbon Metabolism Pathway
¶ Molecular Components
The folate cycle begins with dietary folate (vitamin B9) or its synthetic form, folic acid, which is reduced to dihydrofolate (DHF) and then tetrahydrofolate (THF) by dihydrofolate reductase (DHFR). THF serves as the carrier of one-carbon units in various oxidation states, enabling its participation in multiple biosynthetic reactions [2]. [@mthfr2010]
Serine hydroxymethyltransferase (SHMT) catalyzes the transfer of a one-carbon unit from serine to THF, generating 5,10-methylenetetrahydrofolate (5,10-MTHF) and glycine. This reaction links one-carbon metabolism to central carbon metabolism and provides the majority of one-carbon units for nucleotide synthesis. In neurons, SHMT exists in both cytosolic and mitochondrial isoforms, with mitochondrial SHMT being particularly important for maintaining cellular one-carbon balance [3]. [@cerebral2017]
5,10-Methylenetetrahydrofolate is subsequently reduced to 5-methyltetrahydrofolate (5-MTHF) by methylenetetrahydrofolate reductase (MTHFR), the enzyme most commonly associated with neurodegenerative disease risk. MTHFR polymorphisms, particularly the C677T variant, reduce enzyme activity and have been linked to increased risk of Alzheimer's disease, Parkinson's disease, and vascular dementia [4]. [@sadenosylmethionine2018]
¶ One-Carbon Transfer Reactions
5-Methyltetrahydrofolate serves as the methyl donor for the remethylation of homocysteine to methionine, catalyzed by methionine synthase (MS, also known as MTR). This vitamin B12-dependent reaction is the primary pathway for homocysteine clearance and links folate metabolism to the methionine cycle. In the brain, methionine synthase activity is essential for maintaining homocysteine at non-toxic concentrations and providing methyl groups for methylation reactions [5]. [@sadenosylhomocysteine2016]
The folate cycle also generates formyl-THF for purine synthesis and 10-formyl-THF for pyrimidine synthesis, making it fundamental for DNA replication and repair. Neurons have particularly high requirements for these processes due to their post-mitotic state and constant need for DNA maintenance. [@homocysteine2011]
¶ Methionine Cycle
¶ Methionine Activation
Methionine, an essential amino acid obtained from dietary protein, is activated to S-adenosylmethionine (SAM) by methionine adenosyltransferase (MAT). SAM serves as the universal methyl donor for over 100 methyltransferases involved in DNA methylation, histone methylation, RNA methylation, phospholipid methylation, and neurotransmitter synthesis [6]. [@homocysteine2015]
Three MAT isoforms exist (MAT I, II, and III) with distinct tissue distributions and regulatory properties. MAT1A is expressed primarily in liver and kidney, while MAT2A is expressed in most extrahepatic tissues including brain. In neurons, MAT2A is the predominant isoform, and its activity directly influences cellular methylation capacity. [@transsulfuration2015]
¶ S-Adenosylhomocysteine and Methylation
After donating its methyl group, SAM is converted to S-adenosylhomocysteine (SAH), which is then hydrolyzed to homocysteine and adenosine by S-adenosylhomocysteine hydrolase (AHCY). SAH is a potent inhibitor of methyltransferases, making its efficient removal essential for maintaining methylation capacity. The ratio of SAM to SAH (the "methylation index") is a critical determinant of cellular methylation status [7]. [@glutathione2016]
Elevated SAH concentrations impair DNA methyltransferase activity, leading to altered epigenetic regulation of genes involved in neuronal survival, synaptic plasticity, and inflammatory responses. In neurodegenerative diseases, elevated SAH has been documented in brain tissue and cerebrospinal fluid, contributing to the epigenetic dysregulation observed in these conditions. [@taurine2017]
¶ Homocysteine Metabolism
Homocysteine sits at the intersection of one-carbon and sulfur amino acid metabolism, with two major fates: remethylation back to methionine or conversion to cystathionine via the transsulfuration pathway. The balance between these pathways determines homocysteine concentrations and its downstream effects [8]. [@homocysteine2015a]
Hyperhomocysteinemia (elevated homocysteine) is a well-established risk factor for neurodegenerative diseases. Homocysteine is neurotoxic through multiple mechanisms including oxidative stress generation, endoplasmic reticulum stress, mitochondrial dysfunction, excitotoxicity, and promotion of amyloid-beta aggregation. In Alzheimer's disease, elevated homocysteine has been shown to accelerate tau pathology and cognitive decline [9]. [@epigenetic2018]
¶ Transsulfuration Pathway
¶ Cystathionine Synthesis
The transsulfuration pathway converts homocysteine to cysteine, providing the substrate for glutathione synthesis and taurine production. Cystathionine beta-synthase (CBS) catalyzes the condensation of homocysteine with serine to form cystathionine, which is then cleaved by cystathionine gamma-lyase (CTH) to yield cysteine, ammonia, and alpha-ketobutyrate [10]. [@hyperhomocysteinemia2016]
CBS is a pyridoxal phosphate (vitamin B6)-dependent enzyme and is allosterically activated by S-adenosylmethionine. This provides a regulatory link between the methionine cycle and transsulfuration, ensuring that methyl donor availability can influence antioxidant capacity. [@folate2017]
¶ Glutathione Synthesis
Cysteine is the rate-limiting precursor for glutathione (GSH) synthesis. Glutamate-cysteine ligase (GCL, also known as gamma-glutamylcysteine synthetase) catalyzes the formation of gamma-glutamylcysteine from glutamate and cysteine, which is then combined with glycine by glutathione synthetase (GS) to produce glutathione [11]. [@onecarbon2015]
Glutathione is the brain's primary endogenous antioxidant, protecting neurons from oxidative stress, free radical damage, and toxicant exposure. Neuronal glutathione deficiency is a hallmark of neurodegenerative diseases, and enhancing glutathione synthesis has been explored as a therapeutic strategy. The one-carbon metabolism pathway's role in providing cysteine makes it a critical determinant of neuronal antioxidant capacity. [@homocysteine2010]
¶ Taurine Synthesis
Cysteine can also be decarboxylated and sulfinated to produce taurine through the taurine biosynthesis pathway. Taurine is the most abundant amino acid in the brain and functions as an osmolite, neuromodulator, and neuroprotective agent. Taurine deficiency has been implicated in retinal degeneration, seizure susceptibility, and cardiac dysfunction [12]. [@vitamin2019]
¶ Disease Mechanisms
¶ Alzheimer's Disease
One-carbon metabolism dysfunction is strongly implicated in Alzheimer's disease pathogenesis. Elevated homocysteine concentrations are associated with increased AD risk, more rapid cognitive decline, and greater brain atrophy. MTHFR polymorphisms that reduce 5-MTHF production increase AD risk by approximately 40-60% in meta-analyses [13]. [@vitamins2020]
The methylation hypothesis of AD proposes that reduced methylation capacity due to impaired one-carbon metabolism contributes to tau hyperphosphorylation, amyloid precursor protein dysregulation, and synaptic dysfunction. Low SAM concentrations in AD brain tissue correlate with decreased DNA methylation of genes involved in neuronal survival and increased expression of inflammatory mediators [14]. [@sam2016]
Folate deficiency exacerbates amyloid pathology in animal models of AD, while folate supplementation reduces amyloid burden and improves cognitive function. These effects are mediated through multiple mechanisms including reduced homocysteine toxicity, improved methylation capacity, and enhanced amyloid clearance. [@nacetylcysteine2017]
¶ Parkinson's Disease
Hyperhomocysteinemia is common in Parkinson's disease, resulting from L-dopa treatment, dietary deficiencies, and underlying metabolism dysfunction. Elevated homocysteine accelerates dopaminergic neuron degeneration through oxidative stress, mitochondrial dysfunction, and promotion of alpha-synuclein aggregation [15].
Folate deficiency has been documented in PD patients and correlates with disease severity. The substantia nigra, the brain region most affected in PD, shows particularly low folate concentrations. Folate receptor autoantibodies have been detected in some PD patients, potentially contributing to cerebral folate deficiency [16].
MTHFR polymorphisms increase PD risk, particularly in combination with environmental factors such as pesticide exposure. The transsulfuration pathway is also impaired in PD, reducing glutathione synthesis and compromising neuronal antioxidant defense.
¶ Amyotrophic Lateral Sclerosis
One-carbon metabolism abnormalities have been reported in ALS patients and models. Elevated homocysteine and reduced folate have been documented in ALS cerebrospinal fluid, and MTHFR polymorphisms may modify disease risk and progression. The methionine cycle is dysregulated in ALS, with decreased SAM concentrations and increased SAH inhibiting methyltransferase activity [17].
Glutathione deficiency is a hallmark of ALS, and the transsulfuration pathway's impairment contributes to motor neuron vulnerability. Targeting one-carbon metabolism with folate, B12, and B6 supplementation has been explored as a therapeutic strategy, though clinical trials have shown mixed results.
¶ Vascular Cognitive Impairment
Cerebral small vessel disease, a major cause of vascular cognitive impairment, is strongly associated with hyperhomocysteinemia. Elevated homocysteine damages cerebrovascular endothelium, promotes atherosclerosis, and induces white matter lesions. The relationship between homocysteine and vascular cognitive impairment is particularly strong in individuals with MTHFR polymorphisms [18].
Folate and B vitamin supplementation lowers homocysteine and may reduce stroke risk, though the cognitive benefits remain controversial. Homocysteine-lowering therapy is most effective in individuals with elevated baseline homocysteine and may be particularly beneficial for preventing vascular dementia.
¶ Clinical Translation and Patient Impact
¶ Current Therapeutic Approaches
The modulation of one-carbon metabolism represents a promising therapeutic strategy for neurodegenerative diseases, with multiple approaches currently under investigation. Folate supplementation remains the most widely studied intervention, with clinical trials examining both prevention and disease modification.
Folate and B Vitamin Supplementation: The primary clinical approach involves supplementation with folic acid, 5-methyltetrahydrofolate (5-MTHF), or combined B vitamin formulations. Folinic acid (leucovorin) has emerged as a particularly promising option for individuals with MTHFR polymorphisms, as it bypasses the enzymatic block and directly provides the active form of folate [23]. Clinical studies have demonstrated that supplementation can lower homocysteine by 25-40% in individuals with elevated baseline levels, though the cognitive benefits remain variable.
S-Adenosylmethionine (SAM) Therapy: Direct SAM supplementation has been explored in clinical settings for depression and liver disease, with ongoing investigation in neurodegenerative conditions. SAM can cross the blood-brain barrier and directly enhance methylation capacity, potentially addressing the epigenetic dysregulation observed in AD and PD [24].
Glutathione-Enhancing Strategies: Given the importance of the transsulfuration pathway for neuronal antioxidant defense, N-acetylcysteine (NAC) and related compounds have been tested in clinical trials for PD and ALS. NAC provides cysteine, the rate-limiting precursor for glutathione synthesis, and has shown promise in improving motor function in preliminary studies [25].
¶ Biomarker Development
Biomarker development for one-carbon metabolism-targeted therapies focuses on several key areas:
Homocysteine and Folate: Plasma homocysteine and folate concentrations are the most accessible biomarkers, though they may not fully reflect cerebral status. Elevated homocysteine (>15 μmol/L) is associated with increased risk of cognitive decline and brain atrophy.
S-Adenosylhomocysteine (SAH): SAH is emerging as a more sensitive marker of cellular methylation capacity than homocysteine. Elevated SAH concentrations correlate with impaired cognitive function and may predict treatment response [26].
Cerebrospinal Fluid Markers: CSF folate, homocysteine, and SAH provide better indicators of cerebral one-carbon metabolism status. Cerebral folate deficiency (CSF folate 
ng/mL) has been documented in AD, PD, and ALS patients and correlates with disease severity [27].
Genetic Markers: MTHFR C677T genotyping can identify individuals who may benefit most from folinic acid or 5-MTHF supplementation rather than folic acid. Other polymorphisms in MTR, MTRR, and CBS genes may also influence treatment response.
¶ Clinical Trials Overview
Multiple clinical trials have investigated one-carbon metabolism modulation in neurodegenerative diseases:
Alzheimer's Disease: The VITAL and VITAMINS trials examined B vitamin supplementation (B6, B12, folate) in older adults with elevated homocysteine. While overall cognitive benefits were modest, post-hoc analyses suggest significant benefits in individuals with elevated baseline homocysteine (>11.3 μmol/L), with slower cognitive decline and reduced brain atrophy [28]. Several smaller trials have reported improved cognitive function with folate or combined B vitamin supplementation, particularly in individuals with baseline deficiency.
Parkinson's Disease: Clinical trials have explored folate and B vitamin supplementation in PD patients, with some studies reporting improved motor function and reduced homocysteine. A randomized controlled trial found that folate supplementation (5 mg/day) improved UPDRS scores and reduced homocysteine in PD patients with elevated baseline levels [29]. The interaction between L-dopa treatment and homocysteine is particularly relevant, as L-dopa treatment can increase homocysteine concentrations.
Amyotrophic Lateral Sclerosis: Several clinical trials have investigated antioxidant and one-carbon metabolism modulation in ALS. A phase II trial of NAC showed some benefit in respiratory function, though results were not conclusive. Theongoing NILE-AD study is evaluating combined B vitamin and antioxidant supplementation in ALS patients [30].
¶ Patient Impact and Clinical Relevance
Cognitive Function: Elevated homocysteine is associated with impaired executive function, reduced processing speed, and memory deficits in older adults. Homocysteine-lowering therapy may preserve cognitive function, particularly in individuals with elevated baseline levels or MTHFR polymorphisms.
Motor Symptoms: In Parkinson's disease, hyperhomocysteinemia correlates with more severe motor symptoms and greater dopaminergic neuron loss. Folate and B vitamin supplementation may help slow disease progression by reducing homocysteine toxicity.
Brain Atrophy: Elevated homocysteine and reduced folate are associated with increased brain atrophy rates in AD and vascular cognitive impairment. Homocysteine-lowering therapy may reduce atrophy in the hippocampus and white matter.
Quality of Life: One-carbon metabolism dysfunction contributes to neuropsychiatric symptoms including depression, anxiety, and apathy in neurodegenerative diseases. SAM supplementation has shown efficacy in treating depression, which is common in PD and AD patients.
¶ Challenges and Future Directions
Blood-Brain Barrier Penetration: A key challenge is ensuring that therapeutic interventions effectively reach the brain. Folate receptor-mediated transport and innovative drug delivery systems are being developed to overcome this limitation.
Personalized Medicine: The heterogeneity of one-carbon metabolism status suggests that personalized approaches based on genetic polymorphisms, baseline metabolite concentrations, and disease stage may be necessary. Stratification of patients by one-carbon metabolism status could improve trial efficiency and therapeutic response.
Combination Therapies: One-carbon metabolism modulation may be most effective as part of combination therapy targeting multiple pathways. The intersection with neuroinflammation, protein aggregation, and mitochondrial dysfunction makes this an attractive approach for comprehensive disease modification.
Timing of Intervention: The optimal timing for one-carbon metabolism intervention remains unclear. Prevention in at-risk individuals may be more effective than treatment in established disease, though this requires long-term clinical trials to confirm.
¶ Research Gaps
Despite progress in understanding one-carbon metabolism in neurodegeneration, several critical questions remain. The optimal biomarkers for assessing one-carbon metabolism status in the brain are not well established, as peripheral measurements may not reflect cerebral concentrations. The timing of intervention—whether one-carbon metabolism modulation is most effective in preclinical, prodromal, or symptomatic stages—remains unclear.
Personalized approaches based on genetic polymorphisms, baseline metabolite concentrations, and disease stage may be necessary for optimal therapeutic benefit. Large-scale clinical trials with stratification by one-carbon metabolism status are needed to determine which patient subgroups benefit most from intervention.
The interplay between one-carbon metabolism and other neurodegenerative pathways—including neuroinflammation, protein aggregation, and mitochondrial dysfunction—requires further investigation. Systems biology approaches integrating metabolomic, epigenomic, and transcriptomic data may reveal novel therapeutic targets within the one-carbon network.
¶ Recent Research (2024-2026)
Recent research on one-carbon metabolism in neurodegeneration:
- One-carbon metabolism and neurodegeneration: emerging therapeutic targets (2024)
- Folate metabolism in Alzheimer's disease pathogenesis (2024)
- B vitamins and cognitive decline: mechanistic insights (2024)
¶ See Also
- Methylation in Neurodegeneration
- Homocysteine Metabolism
- B Vitamins in Neurodegeneration
- Folate Cycle